Panelists:
Michael Junkin, PhD
Associate Director of Fluidics and Integration
Elegen
Panelist
Michael Junkin, PhD
Michael Junkin, PhD, leads the instrumentation for Elegen’s DNA synthesis platform. He has more than 15 years of experience in the field of microfluidics, having developed systems to study applications ranging from single-cell immunology and organoid formation to DNA sequencing and synthesis. Junkin received his PhD from the University of Arizona followed by postdocs at ETH Zürich and the University of Chicago.
Brittany Enzmann, PhD
Senior Product Manager
Elegen
Panelist
Brittany Enzmann, PhD
Brittany Enzmann, PhD, serves as senior product manager at Elegen, shaping innovative, cell-free synthetic DNA solutions for next-generation therapeutics. With expertise in synthetic biology, single-cell multi-omics, and genome editing, she is dedicated to advancing technologies that propel scientific discovery. She earned her PhD in biology from the University of California, Los Angeles and completed a postdoctoral fellowship at Arizona State University, where she studied the evolutionary ecology and genetics of social insects.
- Time:
Synthetic biology has long relied on cell-based cloning to address the shortcomings of synthetic DNA. While an effective approach to isolate and amplify sequence-perfect DNA molecules from molecules containing synthesis errors, it has distinct limitations when it comes to producing complex structures such as lengthy DNA repeats or hairpins. Additionally, traditional cloning is a slow, multi-step workflow that carries the risk of contamination from bacterial gDNA and endotoxins.
Cell-free synthesis addresses these issues by completely eliminating cells from the workflow to manufacture highly repetitive or complex sequences rapidly from a manufacturing footprint roughly 10-fold smaller than cell-based processes.
In this GEN webinar, DNA synthesis experts Michael Junkin, PhD, and Brittany Enzmann, PhD, will provide an exclusive first look at Elegen’s GEN II Cell-Free DNA production platform that combines Elegen’s patented split-pool microfluidic synthesizer and cell-free cloning technology. Attendees will learn how the platform utilizes AI and robotics to fully automate the production of long, high-complexity, clonal-quality DNA—eliminating the need for bacterial cells and delivering high accuracy gene synthesis at a lower cost. Key learnings from the webinar include:
- Rapid, cell-free production of linear dsDNA up to 7 kb and plasmids up to 19 kb
- Real-time optimization of production protocols using LLMs
- Production of >10x more genes from a significantly reduced carbon footprint and lower capital costs in comparison to cell-based approaches
- Production of high accuracy, NGS-verified DNA at the price of low-quality gene fragments
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post Next-Level Cell-Free DNA Manufacturing appeared first on GEN – Genetic Engineering and Biotechnology News.
